ASMB—The phase-2a trial design is ok, but I don't buy the stated reason for restricting the trial to e-antigen+ patients.
What is the real reason for the exclusion? Maybe that they don't yet know what dose to use in e-antigen- patients, based on the flattish dose-response curve in phase-1.
Market Data 
Markets 
AI
